SCHEMBL43371

SCHEMBL43371

CCCCCCCCCCCCCCCC(O)C(N)COP(=O)(O)O

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SGPL1 O95470 4/20 0.61
S1PR1 P21453 5/20 0.59
S1PR3 Q99500 5/20 0.59
S1PR2 O95136 4/20 0.59
S1PR5 Q9H228 3/20 0.59
S1PR4 O95977 3/20 0.59
ALDH1A1 P00352 1/20 0.59
TSPO P30536 1/20 0.59
TMEM97 Q5BJF2 1/20 0.59
SIGMAR1 Q99720 1/20 0.59
PLA2G4A P47712 2/20 0.57
CYP2D6 P10635 2/20 0.54
SPHK1 Q9NYA1 1/20 0.54
GMNN O75496 1/20 0.54
LMNA P02545 1/20 0.54
POLB P06746 1/20 0.54
THPO P40225 1/20 0.54
MTOR P42345 1/20 0.54
BLM P54132 1/20 0.54
KDM4E B2RXH2 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18286333 1.00 SGPL1 (0.61) SGPL1S1PR1S1PR3S1PR2S1PR5
SCHEMBL195872 1.00 SGPL1 (0.61) SGPL1S1PR1S1PR3S1PR2S1PR5
SCHEMBL20510812 0.91 SGPL1 (0.58) SGPL1S1PR1S1PR3S1PR2S1PR5
SCHEMBL29472620 0.91 SGPL1 (0.58) SGPL1S1PR1S1PR3S1PR2S1PR5
SCHEMBL17522136 0.91 SGPL1 (0.58) SGPL1S1PR1S1PR3S1PR2S1PR5
SCHEMBL8934971 0.85 SGPL1 (0.66) SGPL1PLA2G4ALPAR5PTPN1LPAR6
SCHEMBL13030814 0.85 SGPL1 (0.66) SGPL1PLA2G4ALPAR5PTPN1LPAR6
SCHEMBL861987 0.83 SGPL1 (0.63) SGPL1PLA2G4ALPAR5PTPN1LPAR6
SCHEMBL1273298 0.83 SGPL1 (0.63) SGPL1PLA2G4ALPAR5PTPN1LPAR6
SCHEMBL21428471 0.81 S1PR2 (0.67) SGPL1S1PR1S1PR3S1PR2S1PR5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 333 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024189238-A1 BIOMARKERS DISCRIMINATING PHENOTYPES OF X-ADRENOLEUKODYSTROPHY INSTITUT D'INVESTIGACIÓ BIOMÈDICA DE BELLVITGE (ES) 2024-09-19 WO claimed
US-20160206633-A1 dhS1P AND USE OF SAME AS AN ANTICANCER THERAPEUTIC AND IMMUNOMODULATOR THE PENN STATE RESEARCH FOUNDATION 2016-07-21 US claimed
US-9274129-B2 Methods and reagents for detecting bioactive lipids LPATH, INC. (US) 2016-03-01 US claimed
EP-2925301-A1 PHOTODYNAMIC DHSIP ANTICANCER THERAPEUTIC AND IMMUNOMODULATOR The Penn State Research Foundation (US) 2015-10-07 EP claimed
EP-2399989-B1 CULTURE MEDIUM AND METHOD FOR INDUCING DIFFERENTIATION INTO ADIPOCYTES FUJIREBIO KK (JP) 2015-04-08 EP claimed
US-20150031055-A1 NOVEL BIOACTIVE LIPID DERIVATIVES, AND METHODS OF MAKING AND USING THE SAME LPATH, INC. (US) 2015-01-29 US claimed
US-20140205669-A1 dhS1P AND USE OF SAME AS AN ANTICANCER THERAPEUTIC AND IMMUNOMODULATOR THE PENN STATE RESEARCH FOUNDATION (US) 2014-07-24 US claimed
WO-2014085461-A1 PHOTODYNAMIC DHSIP ANTICANCER THERAPEUTIC AND IMMUNOMODULATOR THE PENN STATE RESEARCH FOUNDATION (US) 2014-06-05 WO claimed
EP-2027142-B1 Diagnostic reagents and method for their use LPATH INC (US) 2013-03-06 EP claimed
JP-2009541215-A 2009-11-26 JP claimed
EP-2035362-A4 NOVEL BIOACTIVE LIPID DERIVATIVES, IMMUNE-DERIVED MOIETIES REACTIVE THERETO, AND METHODS OF MAKING AND USING THE SAME LPATH INC (US) 2009-08-26 EP claimed
EP-2027142-A4 METHODS AND REAGENTS FOR DETECTING BIOACTIVE LIPIDS LPATH INC (US) 2009-08-19 EP claimed
EP-2035362-A2 NOVEL BIOACTIVE LIPID DERIVATIVES, IMMUNE-DERIVED MOIETIES REACTIVE THERETO, AND METHODS OF MAKING AND USING THE SAME Lpath, Inc. (US) 2009-03-18 EP claimed
EP-2027142-A2 METHODS AND REAGENTS FOR DETECTING BIOACTIVE LIPIDS Lpath, Inc. (US) 2009-02-25 EP claimed
US-20080090303-A1 Methods and Reagents for Detecting Bioactive Lipids APOLLO ENDOSURGERY, INC. 2008-04-17 US claimed
US-20070281320-A1 Novel Bioactive Lipid Derivatives, and Methods of Making and Using Same INNOVATUS LIFE SCIENCES LENDING FUND I, LP 2007-12-06 US claimed
WO-2007140431-A2 NOVEL BIOACTIVE LIPID DERIVATIVES, IMMUNE-DERIVED MOIETIES REACTIVE THERETO, AND METHODS OF MAKING AND USING THE SAME LPATH, INC. (US) 2007-12-06 WO claimed
WO-2007140433-A2 METHODS AND REAGENTS FOR DETECTING BIOACTIVE LIPIDS LPATH, INC. (US) 2007-12-06 WO claimed
US-7300764-B2 Method for identifying agonists and antagonists of the GPR45-like/GPR63 receptor SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-11-27 US claimed
EP-1278850-B1 EDG8 RECEPTOR, ITS PREPARATION AND USE SANOFI AVENTIS DEUTSCHLAND (DE) 2007-06-13 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140205669-A1 dhS1P AND USE OF SAME AS AN ANTICANCER THERAPEUTIC AND IMMUNOMODULATOR DHPS, CD47, DCLRE1A SGPL1 14/4885S1PR1 236/4885S1PR3 479/4885
US-20160206633-A1 dhS1P AND USE OF SAME AS AN ANTICANCER THERAPEUTIC AND IMMUNOMODULATOR DHPS, CD47, DCLRE1A SGPL1 14/4885S1PR1 236/4885S1PR3 479/4885
US-20070281320-A1 Novel Bioactive Lipid Derivatives, and Methods of Making and Using Same SGMS1, SGMS2, LPAR1 SGPL1 36/4885S1PR1 11/4885S1PR3 16/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.